Melospeech Reports 96% of Therapy Goals Met, Exceeded, or Showing Meaningful Progress at Six-Month Reassessment in 2025

TEMECULA, Calif. - EntSun -- Melospeech Inc. today released 2025 internal outcomes data showing that 96% of therapy goals were met, exceeded, or demonstrated meaningful progress at the six-month reassessment mark, based on anonymously collected data from its Speech-Language Pathology evaluation team.

The analysis reflects outcomes across early intervention and pediatric speech-language services delivered throughout the 2025 calendar year in natural environments and virtual settings. All data were aggregated and reviewed without inclusion of any personally identifiable or protected health information.

"This data reflects what happens when families are treated as partners and therapy strategies are embedded into everyday routines," said Dr. Givona Sandiford, speech-language pathologist and founder of Melospeech Inc. "Throughout 2025, our focus remained on sustainable, measurable progress for children and families, especially during a year of significant challenges across pediatric healthcare."

More on EntSun News

• Waliin Completes First Community Fundraising Round and Unveils Major Platform Expansion
• Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
• Is Rolex the Best Watch Ever Made? Experts Weigh In
• Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
• PowerTribe Releases New Heavy Metal Single "The Earthlings Have Died"

2025 Outcome Highlights

• 96% of therapy goals were met, exceeded, or showed meaningful progress at six-month reassessment
• Findings based on anonymized internal evaluation team data collected during 2025
• Services delivered using family coaching, play-based intervention, and natural routines
• Outcomes reviewed as part of standard clinical quality and program design review processes

Melospeech attributes these results to its family-centered coaching model, clinician support infrastructure, and privacy-first internal automation systems designed to reduce administrative burden while maintaining clinical rigor. The company noted these specific outcomes were most notable after 20 regularly attended sessions.

"These outcomes are particularly meaningful given ongoing provider shortages and reimbursement pressures in pediatric services," Sandiford added. "Maintaining quality and access in 2025 required intentional clinical and operational design."

More on EntSun News

• Australian Soulstress NARDIA returns to the U.S. for her January 2026 Tour
• Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
• Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
• AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
• IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever

Commitment to Transparency and Continuous Improvement

Melospeech conducts routine internal program design reviews and six-month reassessments to monitor progress and ensure services remain effective and responsive to family needs. Aggregate, anonymized findings are reviewed internally and may be shared publicly to support transparency and sector-wide learning.

About Melospeech Inc.

Melospeech Inc. is a tech-enabled multi-region pediatric speech-language pathology provider offering in-home, community-based, and virtual services for infants, toddlers, and children across multiple U.S. states. Founded in 2021, the company uses a family-coaching, play-based approach and supports clinicians with privacy-first internal tools, including SLPeaceBot™ and CMSP:B-5™. In late 2025, Melospeech expanded to include occupational therapy and plans to add early childhood infant education supports in 2026.